• 文献检索
  • 文档翻译
  • 深度研究
  • 学术资讯
  • Suppr Zotero 插件Zotero 插件
  • 邀请有礼
  • 套餐&价格
  • 历史记录
应用&插件
Suppr Zotero 插件Zotero 插件浏览器插件Mac 客户端Windows 客户端微信小程序
定价
高级版会员购买积分包购买API积分包
服务
文献检索文档翻译深度研究API 文档MCP 服务
关于我们
关于 Suppr公司介绍联系我们用户协议隐私条款
关注我们

Suppr 超能文献

核心技术专利：CN118964589B侵权必究
粤ICP备2023148730 号-1Suppr @ 2026

文献检索

告别复杂PubMed语法，用中文像聊天一样搜索，搜遍4000万医学文献。AI智能推荐，让科研检索更轻松。

立即免费搜索

文件翻译

保留排版，准确专业，支持PDF/Word/PPT等文件格式，支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述，25分钟生成高质量综述，智能提取关键信息，辅助科研写作。

立即免费体验

A novel loop-structure-based bispecific CAR that targets CD19 and CD22 with enhanced therapeutic efficacy against B-cell malignancies.

作者信息

Zhao Lijun, Li Shuhong, Wei Xiaoyi, Qi Xuexiu, Guo Qiaoru, Shi Licai, Zhang Ji-Shuai, Li Jun, Liu Ze-Lin, Guo Zhi, Zhang Hongyu, Feng Jia, Shi Yuanyuan, Zhang Suping, Cao Yu J

机构信息

State Key Laboratory of Chemical Oncogenomics, Shenzhen Key Laboratory of Chemical Genomics, Peking University Shenzhen Graduate School, Shenzhen 518055, China.

The Shenzhen Pregene Biopharma Company, Ltd., Shenzhen 518118, China.

出版信息

Protein Cell. 2025 Mar 8;16(3):227-231. doi: 10.1093/procel/pwae034.

DOI:10.1093/procel/pwae034
PMID:38823002
原文链接:https://pmc.ncbi.nlm.nih.gov/articles/PMC11891134/
Abstract
摘要
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/d003/11891134/a2863c0726c9/pwae034_fig2.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/d003/11891134/b918fcc5382f/pwae034_fig1.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/d003/11891134/a2863c0726c9/pwae034_fig2.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/d003/11891134/b918fcc5382f/pwae034_fig1.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/d003/11891134/a2863c0726c9/pwae034_fig2.jpg

相似文献

1
A novel loop-structure-based bispecific CAR that targets CD19 and CD22 with enhanced therapeutic efficacy against B-cell malignancies.一种新型的基于环结构的双特异性嵌合抗原受体，其靶向CD19和CD22，对B细胞恶性肿瘤具有增强的治疗效果。
Protein Cell. 2025 Mar 8;16(3):227-231. doi: 10.1093/procel/pwae034.
2
CD19/CD22 bispecific chimeric antigen receptor‑NK‑92 cells are developed and evaluated.开发并评估了CD19/CD22双特异性嵌合抗原受体-NK-92细胞。
Oncol Lett. 2023 Apr 19;25(6):236. doi: 10.3892/ol.2023.13822. eCollection 2023 Jun.
3
Efficacy and safety of CD22-specific and CD19/CD22-bispecific CAR-T cell therapy in patients with hematologic malignancies: A systematic review and meta-analysis.CD22特异性和CD19/CD22双特异性嵌合抗原受体T细胞疗法治疗血液系统恶性肿瘤患者的疗效和安全性：一项系统评价和荟萃分析
Front Oncol. 2022 Dec 29;12:954345. doi: 10.3389/fonc.2022.954345. eCollection 2022.
4
Bispecific CAR-T cells targeting both CD19 and CD22 for therapy of adults with relapsed or refractory B cell acute lymphoblastic leukemia.双特异性 CAR-T 细胞靶向 CD19 和 CD22 治疗复发或难治性 B 细胞急性淋巴细胞白血病成人患者。
J Hematol Oncol. 2020 Apr 3;13(1):30. doi: 10.1186/s13045-020-00856-8.
5
Enhanced efficacy of CD19/CD22 bispecific CAR-T cells with EAAAK linker on B-cell malignancies.EAAAK 接头增强的 CD19/CD22 双特异性 CAR-T 细胞对 B 细胞恶性肿瘤的疗效。
Eur J Haematol. 2024 Jan;112(1):64-74. doi: 10.1111/ejh.14090. Epub 2023 Sep 6.
6
CD22 CAR-T cells secreting CD19 T-cell engagers for improved control of B-cell acute lymphoblastic leukemia progression.分泌CD19 T细胞衔接子的CD22嵌合抗原受体T细胞用于改善对B细胞急性淋巴细胞白血病进展的控制。
J Immunother Cancer. 2025 Apr 30;13(4):e009048. doi: 10.1136/jitc-2024-009048.
7
A Novel bispecific T-cell engager (BiTE) targeting CD22 and CD3 has both in vitro and in vivo activity and synergizes with blinatumomab in an acute lymphoblastic leukemia (ALL) tumor model.一种新型双特异性 T 细胞衔接器（BiTE），靶向 CD22 和 CD3，具有体外和体内活性，并在急性淋巴细胞白血病（ALL）肿瘤模型中与blinatumomab 协同作用。
Cancer Immunol Immunother. 2023 Sep;72(9):2939-2948. doi: 10.1007/s00262-023-03444-0. Epub 2023 May 29.
8
Bispecific CAR T-cells for B-cell Malignancies.双特异性嵌合抗原受体 T 细胞治疗 B 细胞恶性肿瘤。
Expert Opin Biol Ther. 2022 Aug;22(8):1005-1015. doi: 10.1080/14712598.2022.2086043. Epub 2022 Jun 8.
9
Differences in efficacy and safety among CAR-Ts anti-CD19/CD22, anti-CD19, and anti-CD22, in adult patients with relapse/refractory B-cell acute lymphoblastic leukemia: a meta-analysis and systematic review.抗 CD19/CD22、抗 CD19 和抗 CD22 CAR-T 治疗成人复发/难治性 B 细胞急性淋巴细胞白血病的疗效和安全性差异：一项荟萃分析和系统评价。
Leuk Lymphoma. 2023 Nov-Dec;64(11):1822-1831. doi: 10.1080/10428194.2023.2243357. Epub 2023 Aug 7.
10
A novel and efficient CD22 CAR-T therapy induced a robust antitumor effect in relapsed/refractory leukemia patients when combined with CD19 CAR-T treatment as a sequential therapy.一种新型高效的CD22嵌合抗原受体T细胞（CAR-T）疗法与CD19 CAR-T疗法序贯联合使用时，在复发/难治性白血病患者中诱导出了强大的抗肿瘤效果。
Exp Hematol Oncol. 2022 Mar 22;11(1):15. doi: 10.1186/s40164-022-00270-5.

引用本文的文献

1
Computational structural optimization enhances IL13Rα2 - B7-H3 tandem CAR T cells to overcome antigen-heterogeneity-mediated tumor escape.计算结构优化增强IL13Rα2 - B7-H3串联嵌合抗原受体T细胞以克服抗原异质性介导的肿瘤逃逸。
Mol Ther. 2025 Aug 8. doi: 10.1016/j.ymthe.2025.07.044.
2
Novel Loop-Structure-Based CD19/CD22 Dual-Target CAR-T Therapy for High-Risk Diffuse Large B-Cell Lymphoma Presenting with Hemophagocytic Lymphohistiocytosis: A Case Report.基于新型环结构的CD19/CD22双靶点嵌合抗原受体T细胞疗法治疗伴噬血细胞性淋巴组织细胞增生症的高危弥漫性大B细胞淋巴瘤：一例报告
Cancer Manag Res. 2025 Jul 15;17:1389-1398. doi: 10.2147/CMAR.S521944. eCollection 2025.
3

本文引用的文献

1
A novel and efficient tandem CD19- and CD22-directed CAR for B cell ALL.一种新型高效的靶向 CD19 和 CD22 的双靶点 CAR 用于治疗 B 细胞 ALL。
Mol Ther. 2022 Feb 2;30(2):550-563. doi: 10.1016/j.ymthe.2021.08.033. Epub 2021 Sep 1.
2
CAR T cells with dual targeting of CD19 and CD22 in adult patients with recurrent or refractory B cell malignancies: a phase 1 trial.嵌合抗原受体 T 细胞靶向 CD19 和 CD22 治疗成人复发性或难治性 B 细胞恶性肿瘤：一项 1 期试验。
Nat Med. 2021 Aug;27(8):1419-1431. doi: 10.1038/s41591-021-01436-0. Epub 2021 Jul 26.
3
Structural details of monoclonal antibody m971 recognition of the membrane-proximal domain of CD22.
Current Advances and Challenges in CAR-T Therapy for Hematological and Solid Tumors.
嵌合抗原受体T细胞（CAR-T）疗法在血液系统肿瘤和实体瘤治疗中的当前进展与挑战
Immunotargets Ther. 2025 Jun 27;14:655-680. doi: 10.2147/ITT.S519616. eCollection 2025.
4
Research progress on HER2-specific chimeric antigen receptor T cells for immunotherapy of solid tumors.用于实体瘤免疫治疗的HER2特异性嵌合抗原受体T细胞的研究进展
Front Immunol. 2025 May 21;16:1514994. doi: 10.3389/fimmu.2025.1514994. eCollection 2025.
单克隆抗体 m971 识别 CD22 膜近端结构域的结构细节。
J Biol Chem. 2021 Aug;297(2):100966. doi: 10.1016/j.jbc.2021.100966. Epub 2021 Jul 14.
4
Single VHH-directed BCMA CAR-T cells cause remission of relapsed/refractory multiple myeloma.单一VHH导向的BCMA嵌合抗原受体T细胞可使复发/难治性多发性骨髓瘤缓解。
Leukemia. 2021 Oct;35(10):3002-3006. doi: 10.1038/s41375-021-01269-3. Epub 2021 May 24.
5
Trispecific CD19-CD20-CD22-targeting duoCAR-T cells eliminate antigen-heterogeneous B cell tumors in preclinical models.三特异性 CD19-CD20-CD22 双靶点 CAR-T 细胞在临床前模型中消除抗原异质性 B 细胞肿瘤。
Sci Transl Med. 2021 Mar 24;13(586). doi: 10.1126/scitranslmed.abc6401.
6
Nanobody-based chimeric antigen receptor T cells designed by CRISPR/Cas9 technology for solid tumor immunotherapy.基于 CRISPR/Cas9 技术设计的纳米抗体嵌合抗原受体 T 细胞用于实体瘤免疫治疗。
Signal Transduct Target Ther. 2021 Feb 25;6(1):80. doi: 10.1038/s41392-021-00462-1.
7
Engineered T Cell Therapy for Cancer in the Clinic.临床肿瘤的工程化 T 细胞疗法。
Front Immunol. 2019 Oct 11;10:2250. doi: 10.3389/fimmu.2019.02250. eCollection 2019.
8
Resistance Mechanisms to CAR T-Cell Therapy and Overcoming Strategy in B-Cell Hematologic Malignancies.嵌合抗原受体 T 细胞疗法的耐药机制及在 B 细胞血液恶性肿瘤中的克服策略。
Int J Mol Sci. 2019 Oct 10;20(20):5010. doi: 10.3390/ijms20205010.
9
Preclinical Development of Bivalent Chimeric Antigen Receptors Targeting Both CD19 and CD22.靶向CD19和CD22的双价嵌合抗原受体的临床前开发
Mol Ther Oncolytics. 2018 Nov 6;11:127-137. doi: 10.1016/j.omto.2018.10.006. eCollection 2018 Dec 21.
10
Tisagenlecleucel in Adult Relapsed or Refractory Diffuse Large B-Cell Lymphoma.Tisagenlecleucel 治疗成人复发或难治性弥漫性大 B 细胞淋巴瘤。
N Engl J Med. 2019 Jan 3;380(1):45-56. doi: 10.1056/NEJMoa1804980. Epub 2018 Dec 1.